enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. This Biotech IPO Stock Aims to Seize a Multibillion-Dollar ...

    www.aol.com/biotech-ipo-stock-aims-seize...

    Prior to the IPO, it had $62 million in cash and equivalents on its balance sheet. The IPO raised approximately $167 million. So, it should now have around $229 million in cash, a little over four ...

  3. This IPO Biotech Stock Could Be the Next Eli Lilly - AOL

    www.aol.com/ipo-biotech-stock-could-next...

    On Sept. 25, BioAge's stock proceeded with its IPO, which raised gross proceeds of $238.3 million. Before the IPO, it had raised $321 million via several rounds of funding with private investors ...

  4. These 3 Stocks Are Down to Start 2025. What's Going On? - AOL

    www.aol.com/3-stocks-down-start-2025-163400565.html

    Wake up with Breakfast news in your inbox every ... Joining Sonos in the Cloudy Outlook department is biotech company Maderna today. Shares down around 20%. ... at the time of the IPO, they said ...

  5. Roivant Sciences - Wikipedia

    en.wikipedia.org/wiki/Roivant_Sciences

    Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies.

  6. Patrick Soon-Shiong - Wikipedia

    en.wikipedia.org/wiki/Patrick_Soon-Shiong

    In July 2015, Soon-Shiong initiated an IPO for NantKwest (formerly ConkWest) that represented the highest value biotech IPO in history, at a market value of $2.6 billion. [50] In April 2016, the Los Angeles Times reported that Soon-Shiong received a pay package in 2015 from NantKwest worth almost $148 million, making him one of the highest paid ...

  7. Sio Gene Therapies - Wikipedia

    en.wikipedia.org/wiki/Sio_Gene_Therapies

    Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]

  8. 3 “Strong Buy” Biotech Stocks That Recently Went Public - AOL

    www.aol.com/news/3-strong-buy-biotech-stocks...

    This year has seen more than its share of successful IPOs – and some giant flops. The extremes should have been expected, in a year with a record number of new public offerings. The second ...

  9. Acadia Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/Acadia_Pharmaceuticals

    At the time, Acadia and Allergan were collaborating on development of a treatment for glaucoma, and Allergan would retain a 6.3% ownership stake in Acadia after the IPO. [20] However, the company's IPO, which ultimately took place in May 2004, [7] did not fare as well as expected and netted only US$35 million. [21]